In a recent bid Recro Pharma Inc. [REPH] faced a contemporary bid of $3.43 yielding a 49.13% incline where 22.74 million shares have exchanged hands over the last week. REPH amount got a boost by 16.07% or $0.48 versus $2.95 at the end of the prior session. This change led market cap to move at 59.30M, putting the price 130.20% below the 52-week high and -82.14% above the 52-week low. The company’s stock has a normal trading capacity of 22.74 million shares while the relative volume is 60.82.
On 9, November 2020, Recro Reports Third Quarter 2020 Financial Results. According to news published on Yahoo Finance, Company Secures Three-Year Renewal of License and Supply Agreement with Lannett, A Generics Pharmaceutical Company, for Manufacturing of Verelan PM®, Verelan SR® and Verapamil PM.
Analyst Birdseye View:
The most recent analyst activity for Recro Pharma Inc. [NASDAQ:REPH] stock was on January 31, 2019, when it was Resumed with a Buy rating from Janney, which also raised its 12-month price target on the stock to $13. Before that, on October 17, 2019, Stephens Recapitulated an Overweight rating and elevated its amount target to $14. On February 14, 2018, Oppenheimer Initiated an Outperform rating and boosted its price target on this stock to $19. On December 19, 2016, Piper Jaffray Initiated an Overweight rating and increased its price target to $12. On November 14, 2016, Aegis Capital Initiated a Buy rating and increased its price target to $21. On October 03, 2016, Brean Capital Resumed a Buy rating. On September 16, 2016, ROTH Capital Initiated a Buy rating. On November 24, 2015 H.C. Wainwright Resumed a Buy rating and elevated its amount target to $14.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.49 and a peak of $19.21. Right now, according to Wall Street analyst the average 12-month amount target is $6.75. At the most recent market close, shares of Recro Pharma Inc. [NASDAQ:REPH] were valued at $3.43.
Recro Pharma Inc. [NASDAQ:REPH] most recently reported quarterly sales of 19.29 billion, which represented growth of -23.70%. This publicly-traded organization’s revenue is $461,484 per employee, while its income is $21,512 per employee. This company’s Gross Margin is currently 28.50%, its Operating Margin is -0.90%, its Pretax Margin is +4.66, and its Net Margin is +4.66.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 106.45 and the whole liability to whole assets at 100.34. It shows enduring liability to the whole principal at 106.30 and enduring liability to assets at 1.00 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.01 points at 1st support level, the second support level is making up to 2.59. But as of 1st resistance point, this stock is sitting at 4.09 and at 4.75 for 2nd resistance point.
Recro Pharma Inc. [REPH] reported its earnings at -$0.09 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.2/share signifying the difference of 0.11 and 55.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.25 calling estimates for -$0.16/share with the difference of -0.09 depicting the surprise of -56.20%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Recro Pharma Inc. [NASDAQ:REPH] is 3.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.95. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.14.
The most recent insider trade was by HENWOOD GERALDINE, President and CEO, and it was the sale of 80000.0 shares on Apr 17.